Working to beat bowel cancer

We are delighted to work with the Bowel Cancer Foundation Trust on two significant pieces of bowel cancer research.

New Zealand has one of the highest rates of bowel cancer in the world; it is the country’s second highest cause of cancer death.

This substantial donation, left as a legacy, will enable research that aims to enhance clinical practice and improve health outcomes for bowel cancer patients, which could ultimately save lives.

The first piece of research is around familial bowel cancer. It seeks to define an individual’s bowel cancer risk by looking at their family history of the disease, determining if they carry an inherited gene mutation that increases their risk, and therefore improving treatment strategies and outcomes.

Up to 20 percent of people who develop bowel cancer will have a relative with the disease,* and with 90 percent of bowel cancers preventable if caught early enough,** this piece of research has the potential to deliver a breakthrough in increasing patient survival rates.

Bowel Cancer Foundation Trust CEO Georgina Mason

Bowel Cancer Foundation Trust CEO/Founder Georgina Mason says it is exciting for New Zealand to lead this potentially ground-breaking research. “We know that if detected early, bowel cancer can be successfully treated. By better understanding people’s risk of the disease, we can ensure those most at risk receive appropriate care, such as tailored advice and regular screening.”

The second piece of research is around bowel cancer rehabilitation, or more specifically “prehabilitation”, which involves goal setting, exercise training and education before bowel cancer surgery. Through initiating the earliest possible intervention, the research aims to improve the recovery of all bowel cancer patients by exploring the impact of prehabilitation.

Ms Mason says, “Evidence suggests that physical activity following a bowel cancer diagnosis improves both cancer-specific and overall survival. The introduction of prehabilitation could provide insight into a patient’s post-operative rehabilitation needs, which may lead to a faster recovery time. Further benefits could include reducing post-operative complications, and increasing a patient’s motivation and engagement in post-op rehabilitation, therefore improving their quality of life.

“This research will ensure we better understand the role of prehabilitation, as we ultimately work towards developing a framework for providing both pre and post rehabilitation services for all bowel cancer patients throughout New Zealand, enabling them to participate in specially-designed rehabilitation programmes.”

Recognition wall
L-R: Auckland Hospital Foundation Director Candy Schroder and Bowel Cancer Foundation Trust CEO Georgina Mason

Both pieces of research will be delivered under the expertise of Auckland City Hospital – working with the Bowel Cancer Foundation Trust to bring these world-leading research pieces to fruition.

Auckland Hospital Foundation Director Candy Schroder says, “Through our donors, we support research projects that benefit patients and communities, but could not be developed without external investment and generous donations like this one. We are delighted to collaborate with the Bowel Cancer Foundation Trust and Auckland City Hospital clinicians, including the National Medical Lead of the NZ Familial Gastrointestinal Service Associate Professor Susan Parry and Surgical Services Director Dr Arend Merrie, who will lead these hugely important pieces of research.”

Ms Mason adds: “It is so important to shine the spotlight on this disease, which more than 3,200 New Zealanders are diagnosed with each year. Having the pre cursors to bowel cancer myself, and being treated at Auckland City Hospital under the care of Professor Parry and Dr Merrie, I know first-hand the importance of research to help more patients have better outcomes like mine.”

To learn more about leaving a gift in your Will (bequest),  click here.

*Lynch H, de la Chapelle AA. Hereditary colorectal cancer. N Engl J Med 2003;348(10:919-32)
**Bowel Cancer Foundation Trust